That means you're not just satisfying your sweet tooth
(PubMed) Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Hepatic glycogen synthesis is increased through regulation of GYS2 and glycogen phosphorylase via GSK3 and protein phosphatase 1 [15, 16]
Because food stays in your stomach longer, you feel physically full for hours after a meal, preventing premature hunger pangs and snacking
Consequently, these factors participate in regulate ferroptosis and immune escape of ovarian cancer cells, highlighting new therapeutic targets that could alleviate chemotherapy resistance among ovarian cancer patients (7678)